Eureka Therapeutics
Biotechnology company focuses on an immunotherapies for the treatment of cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD278—417m (Dealroom.co estimates Mar 2020.)
Emeryville California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $1.5k | Seed | |
$1.2m | Early VC | ||
$1.7m | Early VC | ||
$21.0m | Series C | ||
$60.0m | Series D | ||
$45.0m | Series E | ||
* | N/A | $20.0m | Debt |
* | $10.6m | Grant | |
| Total Funding | AUD216m | ||
Related Content
Recent News about Eureka Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.